$DOCN stock has now risen 11% today, according to our price data from Polygon. There has been approximately $293,359,720 of trading volume.
Here is what we see in our data on $DOCN (you can track the company live on Quiver's $DOCN stock page):
$DOCN Insider Trading Activity
$DOCN insiders have traded $DOCN stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $DOCN stock by insiders over the last 6 months:
- BRATIN SAHA (Chief Product & Tech Officer) sold 13,010 shares for an estimated $414,628
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$DOCN Hedge Fund Activity
We have seen 203 institutional investors add shares of $DOCN stock to their portfolio, and 129 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WELLINGTON MANAGEMENT GROUP LLP removed 3,287,601 shares (-93.2%) from their portfolio in Q3 2025, for an estimated $112,304,450
- CITADEL ADVISORS LLC added 1,198,532 shares (+126.8%) to their portfolio in Q3 2025, for an estimated $40,941,853
- BALYASNY ASSET MANAGEMENT L.P. added 1,138,996 shares (+inf%) to their portfolio in Q3 2025, for an estimated $38,908,103
- ROYAL BANK OF CANADA added 1,059,782 shares (+501.0%) to their portfolio in Q3 2025, for an estimated $36,202,153
- JANE STREET GROUP, LLC removed 970,053 shares (-97.3%) from their portfolio in Q3 2025, for an estimated $33,137,010
- PRINCIPAL FINANCIAL GROUP INC removed 772,882 shares (-66.0%) from their portfolio in Q3 2025, for an estimated $26,401,649
- MARSHALL WACE, LLP added 664,676 shares (+980.5%) to their portfolio in Q3 2025, for an estimated $22,705,332
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$DOCN Revenue
$DOCN had revenues of $229.6M in Q3 2025. This is an increase of 15.69% from the same period in the prior year.
You can track DOCN financials on Quiver Quantitative's DOCN stock page.
$DOCN Analyst Ratings
Wall Street analysts have issued reports on $DOCN in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- B of A Securities issued a "Buy" rating on 11/06/2025
- Canaccord Genuity issued a "Buy" rating on 11/06/2025
- Morgan Stanley issued a "Overweight" rating on 08/06/2025
To track analyst ratings and price targets for $DOCN, check out Quiver Quantitative's $DOCN forecast page.
$DOCN Price Targets
Multiple analysts have issued price targets for $DOCN recently. We have seen 6 analysts offer price targets for $DOCN in the last 6 months, with a median target of $55.0.
Here are some recent targets:
- Raimo Lenschow from Barclays set a target price of $63.0 on 01/12/2026
- James Fish from Piper Sandler set a target price of $50.0 on 01/05/2026
- Wamsi Mohan from B of A Securities set a target price of $60.0 on 11/06/2025
- Jeff Hickey from UBS set a target price of $48.0 on 11/06/2025
- David Hynes from Canaccord Genuity set a target price of $60.0 on 11/06/2025
- Josh Baer from Morgan Stanley set a target price of $44.0 on 08/06/2025
You can track data on $DOCN on Quiver Quantitative.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
